2023-08-21 16:39:42
Investing.com – SAB Biotherapeutics (NASDAQ: ) second quarter reports match analyst expectations. with revenue lower than expected numbers According to information published on Monday.
SAB Biotherapeutics earnings per share (EPS) were $-0.140 on revenue of $200K. Investing.com previously viewed the number at $-0.140 per share on a $400K earnings basis.
Shares of SAB Biotherapeutics were down 4.06% to $0.730 during the day following the earnings news.
In addition to SAB Biotherapeutics There are other companies in the healthcare sector of the NASDAQ stock market who reported earnings during this month
Eli Lilly previously reported second-quarter earnings of $2.11 per share on revenue of $8.31B, compared with expectations of $1.98 and revenue of $7.58B.
While Novo Nordisk ADR’s recent results were in line with analysts’ forecasts, the performance of the Novo Nordisk ADR is expected to continue. Second-quarter profit was $1.28 per share and revenue was $8.03B, compared with analysts’ expectations. Investing.com It expects earnings per share to be around $1.28 on a $8.21B revenue basis.
Stay up-to-date on company profits through Investing.com earnings calendar
1692648990
#SAB #Biotherapeutics #Earnings #Inline #Revenue #Expectations
